Literature DB >> 2653697

Enoxacin absorption and elimination characteristics.

R D Toothaker1.   

Abstract

Enoxacin, a new fluoroquinolone antibiotic, is rapidly and extensively absorbed after oral administration and has a bioavailability independent of dose and only slightly delayed by concurrent food. Plasma concentrations are similar for both intravenous and oral administration. The t1/2 for enoxacin ranges from 4 to 6 hours, which allows effective twice-daily administration without significant accumulation. Plasma enoxacin concentrations may be slightly higher in elderly subjects, but this change does not necessitate dosage adjustment in older patients with adequate renal function. Enoxacin and ciprofloxacin decrease the clearance of coadministered theophylline, whereas ofloxacin does not appear to greatly alter methylxanthine clearance. Maalox (a magnesium-aluminium hydroxide antacid) significantly decreases the oral bioavailability of ciprofloxacin, ofloxacin and enoxacin, and use of these agents with antacids should be avoided. Enoxacin is a highly effective oral anti-infective agent with excellent bioavailability characteristics, a relatively slow rate of elimination and simple, well-defined requirements for dosage modification in patients with renal dysfunction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653697     DOI: 10.2165/00003088-198900161-00009

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  27 in total

1.  The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin.

Authors:  D E Nix; R W Schultz; R W Frost; A J Sedman; D J Thomas; A W Kinkel; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

2.  Effect of food on enoxacin absorption.

Authors:  A A Somogyi; F Bochner; J A Keal; P E Rolan; M Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

3.  High-performance liquid chromatography and preliminary pharmacokinetics of enoxacin and its 4-oxo metabolite in human plasma, urine and saliva.

Authors:  T B Vree; A M Baars; W J Wijnands
Journal:  J Chromatogr       Date:  1985-10-11

Review 4.  Pharmacokinetics of the penicillins in man.

Authors:  M Barza; L Weinstein
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

5.  The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.

Authors:  R Wolf; R Eberl; A Dunky; N Mertz; T Chang; J R Goulet; J Latts
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

Review 6.  The effect of food on drug bioavailability.

Authors:  R D Toothaker; P G Welling
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

7.  Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.

Authors:  S Toon; K J Hopkins; F M Garstang; L Aarons; A Sedman; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

8.  The influence of quinolone derivatives on theophylline clearance.

Authors:  W J Wijnands; T B Vree; C L van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

9.  Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.

Authors:  T Kalager; A Digranes; T Bergan; T Rolstad
Journal:  J Antimicrob Chemother       Date:  1986-06       Impact factor: 5.790

10.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

View more
  2 in total

1.  Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.

Authors:  C R Marchbanks; D J Mikolich; K H Mayer; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

2.  Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers.

Authors:  U Jaehde; F Sörgel; K G Naber; J Zürcher; W Schunack
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.